Overview Ranolazine Cardioprotection in PCI Status: Terminated Trial end date: 2014-04-01 Target enrollment: Participant gender: Summary The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI). Phase: Phase 2 Details Lead Sponsor: Harvey HahnCollaborator: Gilead SciencesTreatments: Ranolazine